Allelica, Inc

We are thrilled to announce that we are joining forces with Labcorp to make polygenic risk score and precision risk assessments accessible to patients of all ancestral backgrounds. This brings us one step closer to our goal of reducing disease burden with better medicine. Read the full announcement: https://lnkd.in/dN5MWFda

Family history is a well established risk factor for breast cancer, increasing a woman's risk by around 2 times compared to women without family history. But did you know that breast cancer polygenic risk scores (PRSs) can also identify women at 2 times (and even higher) increased risk of breast cancer, and that this genetic risk is largely independent of family history? (https://lnkd.in/em2T5CUE) As physicians routinely ask about family history when assessing a patient's breast cancer risk, shouldn't they also know their PRS? What do you think? If you're interested in implementing multi-ancestry PRSs for breast cancer in your clinic, get in touch Allelica, Inc

👩⚕️ Up to 1 in 3 heart attacks happen in people with no clear clinical risk factors for cardiovascular disease? ⚠ This means that a significant proportion of people who are at risk of heart attack are invisible to risk prediction based on clinical risk factors alone. ✍ Read Allelica, Inc's latest article on PRSs and cardiovascular disease to learn more about the benefits of incorporating PRS tests into cardiovascular disease prevention efforts. https://lnkd.in/erDetat9

Catching breast cancer early when it is localized is crucial, as the five-year relative survival rate is 99%. But how can genetics be used to identify more women at risk of breast cancer? ✍ Check out Allelica, Inc’s new article describing how PRSs are used to mitigate breast cancer disease risk, including: - How primary care physicians can integrate this information into standard clinical breast cancer risk assessments - How integrating PRSs into established risk models like the Tyrer-Cuzick and BOADICEA leads to more accurate risk assessments - How risk conferred by high PRSs is equivalent to risk of disease from rare pathogenic variants If you are interested in using clinical practice, get in touch! https://lnkd.in/g2fQVhvW

👩⚕️ Atherosclerosis is the buildup of fats, cholesterol and other substances in and on the artery walls. These deposits are called plaques and are a major cause of heart disease. ❓ But, did you know that people build these plaques differently, even in the presence of similar levels of LDL-cholesterol? This is in part explained by the interaction between genetics -- measured with polygenic risk scores -- and cholesterol in the blood. Cholesterol does not affect everyone in the same way. Learn more about the science behind this interaction and how clinicians are using PRSs to identify people at increased risk of cardiovascular disease in Allelica, Inc's latest article on PRSs and cardiovasular disease. https://lnkd.in/erDetat9

Did you know that you can use PRS as risk enhancer to identify more patients at high risk of cardiovassular disease? ✍ Allelica, Inc's latest article unpacks the science behind PRSs for cardiovascular disease, including the evidence demonstrating that incorporating PRSs as a risk enhancing factor leads to better and more accurate risk assessments. Get in touch with Allelica to understand how you can use PRSs to better identify your high risk patients [email protected] https://lnkd.in/erDetat9

❤️ Want to know more about how you can prevent more heart attacks and provide a better service to your patients? ❤️ ✍ Check out Allelica’s new article describing how genetics is used to identify high risk patients who fly under the radar of the traditional risk assessment approach. You’ll learn that CAD PRS can: - Be used as a risk enhancer for individuals who are at intermediate clinical risk - Be integrated into clinical risk models - Identify individuals with family history of CVD who are at increased risk If you are interested in using clinical practice, get in touch! [email protected] https://lnkd.in/erDetat9

The transferability of PRSs across different populations has limited their applicability in the past. However, diverse data and innovative methodologies are showing that this is no longer the barrier to implementation that it once was. ✍ In our latest article we describe how Allelica’s ancestry first approach to PRS development and implementation allows us to deliver clinical PRSs for all. https://lnkd.in/evj5SkdC

🌍 At its core, a PRS is based on an understanding of how genetic variation in individuals equates to risk of disease. The ability of PRSs to accurately identify this variation and assign depends on a number of factors, of which genetic ancestry is one of the most important. ✍ Check out our latest blog, where we discuss the challenges and opportunities that variation in genetic ancestry across populations provides when using PRSs. https://lnkd.in/ec83mdrf Are you using PRSs in your practice? What are your concerns about genetic ancestry and PRS?

We are delighted to announce that we are joining forces with Thermo Fisher Scientific to enable world-class, multi-ancestry polygenic risk score (PRS) analysis and reporting at a global scale. Through this collaboration, Thermo Fisher Scientific customers can utilize Allelica’s clinical bioinformatics software seamlessly with Thermo Fisher’s Axiom™ Human Genotyping Microarrays, providing users with a comprehensive and cutting-edge solution for PRS reporting. For information on how you can integrate PRS analysis into your workflows with Thermo Fisher technology, send us an email at [email protected] Read the full announcement: https://lnkd.in/dT2hZDR7